More specifically, we focused our analysis on two large patient cohorts, both including healthy control subject, non‐manifesting carriers of the frequently found LRRK2 G2019S mutation, manifesting patients with the same mutational signature, and PD patients without the LRRK2 mutation. Here, LRRK2 is linked to Parkinson disease.